Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical Progression in Patients with Metastatic Hormone-Sensitive Prostate Cancer By Ogkologos - May 27, 2025 305 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a post-hoc analysis of the ENZAMET study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma March 16, 2026 How Anxiety Impacts People With Cancer and How to Cope February 10, 2022 Treatment for Oropharyngeal Cancer: Investigating Ways to Do Less Harm May 20, 2021 Helicobacter Pylori Infection Modifies the Risk of Gastric Cancer Associated with... March 31, 2023 Load more HOT NEWS Weekend in New England Three-Drug Regimen Improves Protection against GVHD after Stem Cell Transplant World Cancer Day 2023: where does the UK stand? Her Massive Weight Loss Helped Her Feel A Lump In Her...
